Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure
Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
To investigate the effect of hydralazine isosorbide dinitrate on clinical outcomes, symptoms,
cardiac parameters and functional status of African patients hospitalized with AHF and left
ventricular dysfunction during 24 weeks of therapy.
Administration of hydralazine/nitrates will be superior to placebo administration in reducing
HF readmission or death, improving dyspnoea, reducing blood pressure and brain natriuretic
peptide (BNP) in African patients admitted with AHF and left ventricular dysfunction.